Sallam Mariam Madkour, Abou-Aisha Khaled, El-Azizi Mohamed
Department of Microbiology, Immunology, and Biotechnology, Faculty of Pharmacy and Biotechnology, German University in Cairo, New Cairo City, Cairo, Egypt.
Infect Drug Resist. 2016 Dec 8;9:301-311. doi: 10.2147/IDR.S120227. eCollection 2016.
Gram-positive bacteria, especially methicillin-resistant (MRSA) and enterococci, have shown a remarkable ability to develop resistance to antimicrobial agents.
We aimed to assess possible enhancement of the antimicrobial activity of vancomycin, amoxicillin, clarithromycin, and azithromycin by human polyclonal intravenous immunoglobulin G (IVIG) against 34 multidrug-resistant (MDR) bacterial isolates, including MRSA, , and .
Double combinations of the antibiotics with the IVIG were assessed by checkerboard assay, where the interaction was evaluated with respect to the minimum inhibitory concentration (MIC) of the antibiotics. The results of the checkerboard assay were verified in vitro using time-kill assay and in vivo using an invasive sepsis murine model.
The checkerboard assay showed that IVIG enhanced the antimicrobial activity of amoxicillin and clarithromycin against isolates from the three groups of bacteria, which were resistant to the same antibiotics when tested in the absence of IVIG. The efficacy of vancomycin against 15% of the tested isolates was enhanced when it was combined with the antibodies. Antagonism was demonstrated in 47% of the isolates when clarithromycin was combined with the IVIG. Synergism was proved in the time-kill assay when amoxicillin was combined with the antibodies; meanwhile, antagonism was not demonstrated in all tested combinations, even in combinations that showed such response in checkerboard assay.
The suggested approach is promising and could be helpful to enhance the antimicrobial activity of not only effective antibiotics but also antibiotics that have been proven to be ineffective against MDR bacteria. To our knowledge, this combinatorial approach against MDR bacteria, such as MRSA and enterococci, has not been investigated before.
革兰氏阳性菌,尤其是耐甲氧西林金黄色葡萄球菌(MRSA)和肠球菌,已显示出对抗菌药物产生耐药性的显著能力。
我们旨在评估人多克隆静脉注射免疫球蛋白G(IVIG)对34株多重耐药(MDR)细菌分离株(包括MRSA等)增强万古霉素、阿莫西林、克拉霉素和阿奇霉素抗菌活性的可能性。
通过棋盘法评估抗生素与IVIG的双重组合,根据抗生素的最低抑菌浓度(MIC)评估相互作用。棋盘法的结果在体外使用时间杀菌试验进行验证,在体内使用侵袭性败血症小鼠模型进行验证。
棋盘法显示,IVIG增强了阿莫西林和克拉霉素对三组细菌分离株的抗菌活性,这些分离株在无IVIG测试时对相同抗生素耐药。万古霉素与抗体联合使用时,对15%的测试分离株的疗效增强。克拉霉素与IVIG联合使用时,在47%的分离株中显示出拮抗作用。阿莫西林与抗体联合使用时,时间杀菌试验证明有协同作用;同时,在所有测试组合中均未显示拮抗作用,即使在棋盘法中显示有这种反应的组合中也是如此。
所建议的方法很有前景,不仅有助于增强有效抗生素而且有助于增强已被证明对MDR细菌无效的抗生素的抗菌活性。据我们所知,此前尚未研究过针对MRSA和肠球菌等MDR细菌的这种联合方法。